Drugs / TetraMen-T
TetraMen-T
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00631995 | Apr 2008 → Feb 2009 | meningitis, meningococcal infection | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 1 | NCT06165276 | Jul 2006 → Aug 2008 | meningococcal infection | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TetraMen-T | “Safety and Immunogenicity of a Quadrivalent Meningococcal (A, C, Y, and W-135) Tetanus Protein Conjugate Vaccine (TetraMen-T) in Toddlers” NCT00631995 ↗ |
| Known as | Meningococcal (Groups A, C, Y and W-135) Polysaccharide Tetanus Protein Conjugate Vaccine | “Meningococcal (Groups A, C, Y and W-135) Polysaccharide Tetanus Protein Conjugate Vaccine (TetraMen-T).” NCT06165276 ↗ |
| Modality | Vaccine | “quadrivalent meningococcal (A, C, Y, and W-135) Tetanus Protein Conjugate Vaccine (TetraMen-T)” NCT00631995 ↗ |
| Route | Intramuscular | “Route of administration:Intramuscular (IM)” NCT06165276 ↗ |